Rezolute, Inc. Announces Positive Interim Data for Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Key Points & Investor Highlights
- Positive interim results: Rezolute reported promising interim data from its ongoing Phase 3 upLIFT study evaluating ersodetug for tumor-induced hyperinsulinism (HI), a rare and severe form of hypoglycemia.
- 50% enrollment milestone: The study is now halfway to its targeted enrollment, with 8 participants out of a planned 16 already recruited.
- Strong efficacy signals: Of the 8 participants, 6 have already met the primary endpoint responder criterion—achieving at least a 50% reduction from baseline in intravenous glucose requirements (glucose infusion rate, GIR) within the pivotal 8-week treatment phase. Notably, all 6 also achieved complete discontinuation of IV glucose, indicating substantial clinical benefit.
- Safety profile: Ersodetug has been well-tolerated with no drug-related adverse events or other safety concerns reported to date, both in the pivotal and extension phases.
- Extension phase: Participants completing the 8-week pivotal phase have elected to continue into an open-label extension, with cumulative treatment duration up to 6 months, underscoring sustained benefit and tolerability.
- Patient withdrawal: One participant withdrew due to progression of metastatic cancer and transitioned to hospice care; this individual was counted as a non-responder for endpoint purposes.
- Topline results timeline: Final topline results from the fully enrolled study are expected in the second half of 2026.
- Potential universality: Interim results support the potential for ersodetug to treat various forms of HI—including congenital, tumor-associated, and post-surgical hypoglycemia—addressing a significant unmet medical need.
- Regulatory engagement: Rezolute is actively engaging with the FDA to define the path forward for congenital HI indication, in addition to tumor HI.
Detailed Study Summary
The upLIFT Phase 3 study is a pivotal, single-arm, open-label trial targeting approximately 16 participants suffering from uncontrolled hypoglycemia caused by either insulinoma (islet cell tumors) or non-islet cell tumors. Eligible participants require continuous intravenous (IV) glucose and receive weekly doses of ersodetug (9 mg/kg) for 8 weeks, as an adjunct to standard of care. After the initial 8-week period, participants may opt into a long-term extension phase.
The primary endpoint is the proportion of participants achieving at least a 50% reduction from baseline in IV glucose requirements (GIR). Additional endpoints include: time to discontinuation of IV glucose, time to hospital discharge, frequency and duration of hypoglycemic events (measured both by self-monitoring and continuous glucose monitoring), and patient-reported quality of life.
Background and Market Opportunity
Tumor hyperinsulinism (HI) is a rare, life-threatening disorder resulting from over-activation of the insulin receptor due to either islet cell tumors or non-islet cell tumors. Insulinomas are the most common ICTs, triggering excess insulin production and severe hypoglycemia. NICTs, including hepatocellular carcinomas, can produce insulin-like substances (IGF-2 variants) that activate the insulin receptor. With high morbidity and mortality rates, current treatment options are limited, highlighting a significant unmet need for new therapies.
Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor, reducing over-activation by insulin and related substances (such as IGF-2). It acts downstream of glucose absorption, incretin hormones, and pancreatic insulin secretion, making it a potentially universal treatment for refractory hypoglycemia across congenital and acquired HI, including post-surgical cases.
Implications for Shareholders
- Positive interim efficacy: Early data suggest ersodetug may deliver robust, durable responses for patients with severe HI who have few alternatives. This is a strong signal of potential commercial viability if confirmed in final results.
- Safety profile: The absence of drug-related adverse events is crucial for regulatory approval and market adoption, especially for a rare disease population.
- Regulatory progress: Continued FDA engagement, combined with the strong interim efficacy data, improves the probability of approval for both tumor and congenital HI indications.
- Market expansion: If ersodetug becomes a universal treatment for HI (including congenital, acquired, and post-surgical forms), the addressable market and revenue potential would be significantly expanded.
- Upcoming catalysts: Topline results expected in 2H 2026 are a key inflection point. Positive results would likely be price-sensitive and could materially impact Rezolute’s share value.
Contact Information
- Christen Baglaneas: [email protected] | 508-272-6717
- Carrie McKim: [email protected] | 336-608-9706
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are inherently uncertain, and actual results may differ materially from those anticipated. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. Rezolute, Inc. undertakes no obligation to update forward-looking statements, except as required by law. Important risk factors are detailed in Rezolute’s filings with the SEC.
